Google
PALI — PALISADE BIO INC (Healthcare >> Biotechnology)
PALI FAQ
What is PALI's ROE?
PALISADE BIO INC reports a Return on Equity (ROE) of -18.96%.
What is PALI's dividend yield?
PALISADE BIO INC offers a dividend yield of 0.00%.
What is PALI's Deepscope Quality Score?
Deepscope rates PALI's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PALI?
Deepscope's AI Timing Score for PALI is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PALI belong to?
PALISADE BIO INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.93
Price
0.07
(3.76%)
Day Change
|
|
|---|
PALI, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.93 |
| PBV / Sector |
2.89 / 4.48
|
| Earning Per Share | -0.13 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
5.32 M
GREAT
|
| Average 1W Daily Value |
5.13 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:20 |
| Symbol | PALI |
| Name | PALISADE BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 173.58 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 368.41 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4600 South Syracuse Street, Denver, CO, United States, 80237
Phone: 858 704 4900
Website: https://www.palisadebio.com
Sector: Healthcare >> Biotechnology
Description: Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
